SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-24-266104 from Coya Therapeutics, Inc. (COYA)

Coya Therapeutics, Inc.
Date: Nov. 26, 2024 · CIK: 0001835022 · Accession: 0001193125-24-266104

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-283366

Date
November 26, 2024
Author
Arun Swaminathan
Form
CORRESP
Company
Coya Therapeutics, Inc.

Letter

Re:

November 26, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Coya Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-283366)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on November 29, 2024, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
COYA THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 November 26, 2024

VIA EDGAR

 United States Securities and Exchange
Commission

 Division of Corporation Finance

 100 F Street,
N.E.

 Washington, D.C. 20549

 Re:

 Coya Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-283366)

 Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration
Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on November 29, 2024, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the
effectiveness of the Registration Statement or with any questions.

Very truly yours,

 COYA THERAPEUTICS, INC.

By:

 /s/ Arun Swaminathan

Name:

Arun Swaminathan

Title:

 Chief Executive Officer

 (Principal Executive
Officer)